Daily Medication Pearl: Benralizumab (Fasenra)

Medication Pearl of the Day: Benralizumab (Fasenra)

Indication: Benralizumabis an interleukin-5 receptor (IL-5Rα) alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.

Insight:

• Dosing: Administer by subcutaneous injection. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter
• Dosage form: Injection 30 mg/mL solution in a single-dose prefilled syringe. Injection 30 mg/mL solution in a single dose autoinjector Fasenra Pen.
• Adverse events (AEs): Most common AEs are headache and pharyngitis.
• Mechanism of action: Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the IL-5Rα with a dissociation constant of 11 pM.
• Manufacturer: AstraZeneca

Sources:

• Fasenra Prescribing Information (den8dhaj6zs0e.cloudfront.net)
• FASENRA® (benralizumab) for Severe Eosinophilic Asthma | For HCPs (fasenrahcp.com)
• fasenra - Google Search